FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912603519> ?p ?o ?g. }

• W2912603519 abstract "Primary immunodeficiencies represent a spectrum of disorders characterised by impaired development and function of the immune system with the more severe forms being lethal in infancy. Haematopoietic stem cell transplant is a curative treatment for many of these conditions but is limited by the availability of suitable donors and toxicities associated with cytoreductive chemotherapy and human leucocyte antigen disparity. Gene therapy strategies offer an alternative management option and have been developed for a number of disorders, with clinical trials underway for adenosine deaminase-deficient-severe combined immune deficiency (SCID), X-linked SCID, X-linked chronic granulomatous disease and Wiskott–Aldrich Syndrome. Initial trials using gammaretroviral vector-mediated gene transfer showed impressive efficacy but were complicated by vector insertion driven leukaemia in some patients. Newer designs using modified vectors are likely to have an improved safety profile and the results of ongoing clinical trials may pave the way for gene therapy as a feasible management option for some children with PIDs. Key Concepts: In gene therapy, a patient's own haematopoietic stem cells are harvested, transduced with a viral vector containing a corrected copy of the defective gene and then returned to the patient. A gene therapy procedure can be curative for patients with specific forms of severe combined immune deficiency (SCID), namely adenosine deaminase-deficient SCID (ADA-SCID) or X-linked SCID. Gene therapy also potentially offers definitive treatment for some non-SCID PIDs including CGD and WAS although clinical trials are at early stages and those performed using gammaretroviral vectors offered only transient clinical benefit, if any. Owing to the nature of the gammaretroviral vectors used in early trials several patients treated developed leukaemias or myelodysplasia. Lentiviral vectors with an improved biosafety profile have since been developed, which reduce the risk of this happening again. Targeted gene correction where the gene of interest is corrected in situ using meganuclease technology is currently being investigated as a future strategy, which may improve both the safety and efficacy of gene therapy procedures." @default.
• W2912603519 created "2019-02-21" @default.
• W2912603519 creator A5004972535 @default.
• W2912603519 creator A5015856478 @default.
• W2912603519 creator A5073418464 @default.
• W2912603519 date "2013-06-13" @default.
• W2912603519 modified "2023-10-16" @default.
• W2912603519 title "Gene Therapy for Primary Immunodeficiency" @default.
• W2912603519 cites W1966417933 @default.
• W2912603519 cites W1966530560 @default.
• W2912603519 cites W1966983163 @default.
• W2912603519 cites W1977486219 @default.
• W2912603519 cites W1978660935 @default.
• W2912603519 cites W1980449150 @default.
• W2912603519 cites W1981799120 @default.
• W2912603519 cites W1984320737 @default.
• W2912603519 cites W1985071555 @default.
• W2912603519 cites W1985089042 @default.
• W2912603519 cites W1996788733 @default.
• W2912603519 cites W2001082593 @default.
• W2912603519 cites W2003310057 @default.
• W2912603519 cites W2012738976 @default.
• W2912603519 cites W2013940523 @default.
• W2912603519 cites W2017608059 @default.
• W2912603519 cites W2023456870 @default.
• W2912603519 cites W2032678451 @default.
• W2912603519 cites W2037256495 @default.
• W2912603519 cites W2037588200 @default.
• W2912603519 cites W2039333435 @default.
• W2912603519 cites W2043358334 @default.
• W2912603519 cites W2044801924 @default.
• W2912603519 cites W2047689196 @default.
• W2912603519 cites W2050997453 @default.
• W2912603519 cites W2052936135 @default.
• W2912603519 cites W2053045221 @default.
• W2912603519 cites W2054062980 @default.
• W2912603519 cites W2056896498 @default.
• W2912603519 cites W2057879405 @default.
• W2912603519 cites W2066099080 @default.
• W2912603519 cites W2073643492 @default.
• W2912603519 cites W2073676586 @default.
• W2912603519 cites W2085759579 @default.
• W2912603519 cites W2086409978 @default.
• W2912603519 cites W2088257569 @default.
• W2912603519 cites W2091375730 @default.
• W2912603519 cites W2092633851 @default.
• W2912603519 cites W2100304556 @default.
• W2912603519 cites W2107046588 @default.
• W2912603519 cites W2108131113 @default.
• W2912603519 cites W2119324304 @default.
• W2912603519 cites W2121444412 @default.
• W2912603519 cites W2124086076 @default.
• W2912603519 cites W2127433915 @default.
• W2912603519 cites W2137409670 @default.
• W2912603519 cites W2139028184 @default.
• W2912603519 cites W2147859982 @default.
• W2912603519 cites W2154172872 @default.
• W2912603519 cites W2162773306 @default.
• W2912603519 cites W2165156434 @default.
• W2912603519 cites W2915755317 @default.
• W2912603519 cites W1938795169 @default.
• W2912603519 doi "https://doi.org/10.1002/9780470015902.a0024635" @default.
• W2912603519 hasPublicationYear "2013" @default.
• W2912603519 type Work @default.
• W2912603519 sameAs 2912603519 @default.
• W2912603519 citedByCount "1" @default.
• W2912603519 countsByYear W29126035192012 @default.
• W2912603519 crossrefType "reference-entry" @default.
• W2912603519 hasAuthorship W2912603519A5004972535 @default.
• W2912603519 hasAuthorship W2912603519A5015856478 @default.
• W2912603519 hasAuthorship W2912603519A5073418464 @default.
• W2912603519 hasBestOaLocation W29126035192 @default.
• W2912603519 hasConcept C104317684 @default.
• W2912603519 hasConcept C111599444 @default.
• W2912603519 hasConcept C126322002 @default.
• W2912603519 hasConcept C203014093 @default.
• W2912603519 hasConcept C2777408962 @default.
• W2912603519 hasConcept C2778153459 @default.
• W2912603519 hasConcept C2778175462 @default.
• W2912603519 hasConcept C2779019163 @default.
• W2912603519 hasConcept C2779468541 @default.
• W2912603519 hasConcept C2781161190 @default.
• W2912603519 hasConcept C28328180 @default.
• W2912603519 hasConcept C2911091166 @default.
• W2912603519 hasConcept C32470452 @default.
• W2912603519 hasConcept C40767141 @default.
• W2912603519 hasConcept C535046627 @default.
• W2912603519 hasConcept C54355233 @default.
• W2912603519 hasConcept C71924100 @default.
• W2912603519 hasConcept C86803240 @default.
• W2912603519 hasConcept C8891405 @default.
• W2912603519 hasConcept C92087593 @default.
• W2912603519 hasConceptScore W2912603519C104317684 @default.
• W2912603519 hasConceptScore W2912603519C111599444 @default.
• W2912603519 hasConceptScore W2912603519C126322002 @default.
• W2912603519 hasConceptScore W2912603519C203014093 @default.
• W2912603519 hasConceptScore W2912603519C2777408962 @default.
• W2912603519 hasConceptScore W2912603519C2778153459 @default.
• W2912603519 hasConceptScore W2912603519C2778175462 @default.
• W2912603519 hasConceptScore W2912603519C2779019163 @default.

• next